Replies to post #99043 on Bioelectronics Corp (BIEL)

[Dominique21]

5 star reviews continue on amazon:

Actipatch is a Must Have Miracle at Home
ByAmazon Customeron February 19, 2017
Verified Purchase
My wife used it on her knees for a few days and the pain disappeared as a miracle. She is walking with no pain. I used hers for a few days on my tailbone. I could not believe the result. I have been trying to clear the mild pain in that area for almost a year now. Next is on my hand following the sciatic nerve. What a Miracle.

ByR. Hegbergon February 19, 2017
Verified Purchase
My husband found this about 8 years ago when searching for pain relief from whiplash. Within 3 weeks was pain free, off meds and no longer getting treatments. Has been used several times since for tendonitus, back pain, and ankle sprain. Used to get from friends in Canada, happy to be able to order in U.S.A finally.

Amazing Healing Device
ByDavidCKon February 19, 2017
Verified Purchase
I just started running again and have developed a few aches and pains. I bought this trial product just to keep on hand. Well I'm glad I did because I've already used it. I also bought the smart insole off ActiPatch's website and found it beneficial. Two recommendations. 1. add an on/off switch and 2. make a full length insole. I still gave this product a 5/5 because it is literally amazing.

[Rheeper]

Have you even looked at the financials? First of all, the break even level is much higher than $750k in incremental sales but for argument's sake lets say they break even at the OP level. But annual interest expense is ~$450-$500k so they would still be loss making at the net profit level.

Your comment on PE reflects a misunderstanding of valuations. Luckily, most OTC investors probably don't care anyways.

[Simpsonly]

You are correct but so is Rheeper. . . . . earnings based projections are of little use; rather, it is what you are doing starting with sales based potentials. Very sophisticated M&A experts will work up market analyses until they are blue in the face to crunch their 'guesstimates' of what they think ActiPatch will do in thousand of markets and many scenarios month by month, year by year for the 1st 5 years and beyond. They will crunch how much pain market share, Rx and OTC, they can take from competitors in the pain space.

The databases on the pain space are deep and the right people will be able to determine how many ActiPatch devices will be purchased in what areas and by whom and how often. All that will form the basis for sales and profitability projections and finally to a number. Then the securing of ActiPatch will be weighed against acquiring the marketing and sales rights to ActiPatch, and not, and the effect on corporate profits of each will be weighed by an M&A team to arrive at the number to plug into M&A discussions . . . . .

Then, strategists and tacticians will get a chew on it and finally a corporate team will kick around how badly they want it and what they are prepared to pay or share to get it at the corporate level. My gut tells me there will be more than one suitor and it will be a very substantial number. 'FDA OTC Clearance' and 'USPTO patented IP' are very powerful assets.